phase 0_trial_initiation
saveWashington University School of Medicine — asciminib hydrochloride (Phase 0 Trial Initiation)
community read0 votes
Therapy area: Oncology. Indication: Brain Tumor
Data sources
globaldata
Found something off?
drug timeline · 8
- phase 2 initiationNovartis AG — asciminib hydrochloride (Phase II Trial Initiation)Apr 25, 2026 · 166d ago
- approvalSCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalNov 25, 2025 · 317d ago
- approvalSCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalOct 2, 2025 · 371d ago
- approvalSCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalOct 29, 2024 · 709d ago
- approvalSCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalOct 29, 2024 · 709d ago
- approvalSCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalAug 7, 2024 · 792d ago
- approvalSCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalJun 18, 2024 · 842d ago
- approvalSCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalNov 8, 2023 · 1065d ago
related news · 1
🐶 often sniffed alongside
top 7- drugSCEMBLIX46 co-mentions · 13 sources
- tagApproval44 co-mentions · 11 sources
- tagSmall Molecule22 co-mentions · 11 sources
- tagOncology3 co-mentions · 2 sources
- company$NVSNOVARTIS AG1 co-mentions · 1 sources
- company$NVSEFNOVARTIS AG1 co-mentions · 1 sources
- companyWashington University School of Medicine1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that